Chemical Structure : XY0206
Catalog No.: PC-27991Not For Human Use, Lab Use Only.
XY0206 is a potent and oral FMS-like tyrosine kinase 3 (FLT3) inhibitor with IC50 of 0.7 nM, 5.27 nM and 6.92 nM for FLT3-ITD, FLT3 and RET, suppresses downstream STAT5, AKT, and ERK signaling, resulting in apoptosis in FLT3-ITD AML cells.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
XY0206 is a potent and oral FMS-like tyrosine kinase 3 (FLT3) inhibitor with IC50 of 0.7 nM, 5.27 nM and 6.92 nM for FLT3-ITD, FLT3 and RET, suppresses downstream STAT5, AKT, and ERK signaling, resulting in apoptosis in FLT3-ITD AML cells.
XY0206 strongly inhibits FLT3, along with other RTKs including RET and PDGFRβ (IC50=26 nM), inhibits PDGFRα, KDR, KIT, and ALK with IC50 of 158-675 nM.
XY0206 exhibits preferential anti-leukemic activity in FLT3-ITD-mutated AML cells with IC50 of 5.88 nM, 14.97 nM, and 4.35 nM for MV4-11, MOLM13, and Ba/F3-FLT3-ITD.
XY0206 retains activity against FLT3-ITD AML cells harboring the FLT3-F691L gatekeeper mutation.
XY0206 retains activity in FLT3-ITD AML with growth factor-associated and acquired resistance.
XY0206 demonstrates anti-leukemic activity with favorable tolerability in patient-derived AML blasts and preclinical mouse models.
| M.Wt | 404.87 | |
| Formula | C20H22ClFN4O2 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Shen L, et al. J Clin Invest. 2026 Sep 1:e204701.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright